Literature DB >> 889513

Carbonic anhydrase inhibitor side effects. Serum chemical analysis.

D L Epstein, W M Grant.   

Abstract

Multiple serum chemical values were examined in 92 patients with chronic glaucoma who were treated with the carbonic anhydrase inhibitors (CAIs) acetazolamide or methazolamide, seeking relationships between serum composition and symptomatic side effects. Of the 92 patients, 44 complained of a symptom-complex of malaise, fatigue, weight loss, depression, anorexia, and loss of libido, which we have found most commonly to threaten continuation of therapy. Patients who had this symptom complex were significantly more acidotic than those without it. Ten of 24 patients who had chemical evidence of excessive acidosis reported a dramatic alleviation of symptoms when sodium bicarbonate was administered, although their serum CO2-combining power changed little. There was no correlation of the symptom complex with serum potassium concentration, except in a few patients who were simultaneously receiving chlorothiazide diuretics for systemic hypertension and who became frankly hypokalemic.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 889513     DOI: 10.1001/archopht.1977.04450080088009

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  27 in total

1.  Metalloprotein-inhibitor binding: human carbonic anhydrase II as a model for probing metal-ligand interactions in a metalloprotein active site.

Authors:  David P Martin; Zachary S Hann; Seth M Cohen
Journal:  Inorg Chem       Date:  2013-05-24       Impact factor: 5.165

2.  Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.

Authors:  Michael Wall; Michael P McDermott; Karl D Kieburtz; James J Corbett; Steven E Feldon; Deborah I Friedman; David M Katz; John L Keltner; Eleanor B Schron; Mark J Kupersmith
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

3.  L-662,583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animals.

Authors:  M F Sugrue; P Gautheron; P Mallorga; T E Nolan; S L Graham; H Schwam; K L Shepard; R L Smith
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

4.  Effects of acetazolamide on kidney function in type 1 (insulin-dependent) diabetic patients with diabetic nephropathy.

Authors:  P Skøtt; E Hommel; N E Bruun; S Arnold-Larsen; H H Parving
Journal:  Diabetologia       Date:  1988-11       Impact factor: 10.122

Review 5.  Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.

Authors:  J A Balfour; M I Wilde
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

6.  Acetazolamide and symptomatic metabolic acidosis in mild renal failure.

Authors:  D N Maisey; R D Brown
Journal:  Br Med J (Clin Res Ed)       Date:  1981-12-05

7.  Laser trabeculoplasty and decay effects in glaucoma patients.

Authors:  A I Fink; A J Jordan
Journal:  J R Soc Med       Date:  1984-02       Impact factor: 5.344

8.  Potassium supplements during treatment of glaucoma with acetazolamide.

Authors:  A S Critchlow; S N Freeborn; R A Roddie
Journal:  Br Med J (Clin Res Ed)       Date:  1984-07-07

9.  Hyperkalaemia induced by carbonic anhydrase inhibitor.

Authors:  Y Wakabayashi
Journal:  Br J Ophthalmol       Date:  1991-03       Impact factor: 4.638

Review 10.  Post-penetrating keratoplasty glaucoma.

Authors:  Tanuj Dada; Anand Aggarwal; K B Minudath; M Vanathi; Sunil Choudhary; Viney Gupta; Ramanjit Sihota; Anita Panda
Journal:  Indian J Ophthalmol       Date:  2008 Jul-Aug       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.